Davis L Temple

US Patent:

20030224343, Dec 4, 2003

Filed:

Jan 28, 2003

Appl. No.:

10/352254

Inventors:

Robert Jones - San Diego CA, US
Davis Temple - Wallingford CT, US
J. McIntosh - Salt Lake City UT, US
Baldomero Olivera - Salt Lake City UT, US

International Classification:

A01N001/02
A61K038/16

US Classification:

435/001100, 514/002000

Abstract:

The invention relates to -PVIIA-related conotoxins and their use as organ protecting agents, i.e., organ protectants. These conotoxins can be used for arresting, protecting or preserving an organ, such as a circulatory organ, a respiratory organ, a urinary organ, a digestive organ, a reproductive organ, an endocrine organ or a neurological organ. These conotoxins can also be used for arresting, protecting or preserving somatic cells.

US Patent:

20040092447, May 13, 2004

Filed:

Jul 28, 2003

Appl. No.:

10/627685

Inventors:

Karen Pemberton - Guilford CT, US
Davis Temple - Clinton CT, US
Richard Layer - Sandy UT, US
R. McCabe - Salt Lake City UT, US
Robert Jones - San Diego CA, US

Assignee:

Cognetix, Inc. - Salt Lake City UT

International Classification:

A61K038/17
A61K038/10

US Classification:

514/012000, 514/013000

Abstract:

The invention relates to uses of kappa-conotoxin PVIIA ( -PVIIA), analogs and derivatives for activating ATP-sensitive K channels. The activation of ATP-sensitive K channels is useful for opening Kchannels which can be used to treat a wide range of disease and injury states, including cerebral and cardiac ischemia and asthma.

US Patent:

20060040312, Feb 23, 2006

Filed:

Oct 27, 2005

Appl. No.:

11/259039

Inventors:

Karen Pemberton - Guilford CT, US
Davis Temple - Clinton CT, US
Richard Layer - Sandy UT, US
R. McCabe - Salt Lake City UT, US
Robert Jones - San Diego CA, US

Assignee:

Cognetix, Inc. - Salt Lake City UT

International Classification:

C12Q 1/68
A61K 38/16

US Classification:

435006000, 514007000, 514012000

Abstract:

The invention relates to uses of kappa-conotoxin PVIIA (κ-PVIIA), analogs and derivatives for activating ATP-sensitive K channels. The activation of ATP-sensitive K channels is useful for opening Kchannels which can be used to treat a wide range of disease and injury states, including cerebral and cardiac ischemia and asthma.

US Patent:

20060257843, Nov 16, 2006

Filed:

Jul 21, 2006

Appl. No.:

11/490133

Inventors:

Robert Jones - San Diego CA, US
Davis Temple - Wallingford CT, US
J. McIntosh - Salt Lake City UT, US
Baldomero Olivera - Salt Lake City UT, US

Assignee:

Cognetix, Inc. - Salt Lake City UT
University of Utah Research Foundation - Salt Lake City UT

International Classification:

A01N 1/02

US Classification:

435001100, 514012000

Abstract:

The invention relates to κ-PVIIA-related conotoxins and their use as organ protecting agents, i.e., organ protectants. These conotoxins can be used for arresting, protecting or preserving an organ, such as a circulatory organ, a respiratory organ, a urinary organ, a digestive organ, a reproductive organ, an endocrine organ or a neurological organ. These conotoxins can also be used for arresting, protecting or preserving somatic cells.

US Patent:

46347038, Jan 6, 1987

Filed:

Oct 25, 1985

Appl. No.:

6/791182

Inventors:

Neil M. Kurtz - Westport CT
Roger E. Newton - Evansville IN
Davis L. Temple - Wallingford CT

Assignee:

Bristol-Myers Company - New York NY

International Classification:

A61K 3150
A61K 31495

US Classification:

514252

Abstract:

Buspirone and its pharmaceutically acceptable salts are useful in alleviation of panic disorders which can take the form of clinical syndromes comprising, for example, panic attacks, agoraphobia and phobic anxiety.

US Patent:

45741298, Mar 4, 1986

Filed:

May 23, 1985

Appl. No.:

6/737119

Inventors:

Xina Nair - East Amherst NY
Davis L. Temple - Wallingford CT

Assignee:

Bristol-Myers Company - New York NY

International Classification:

A61K 3124
A61K 31405

US Classification:

514540

Abstract:

New compositions using particular. beta. sub. 2 agonists and vehicle materials have been prepared and are useful for producing a topical anti-inflammatory effect in mammals. The selected. beta. sub. 2 agonists have previously not been known to exhibit topical anti-inflammatory activity. The compositions can be for example in the form of sprays, ointments, creams, gels, lotions, and suppositories, all of which are to be applied to the mammal topically, as opposed to systemically.

US Patent:

47820608, Nov 1, 1988

Filed:

Jul 29, 1987

Appl. No.:

7/079190

Inventors:

Neil Kurtz - Weston CT
Roger E. Newton - Evansville IN
Davis L. Temple - Wallingford CT

Assignee:

Bristol-Myers Company - New York NY

International Classification:

A61K 3150
A61K 31495

US Classification:

514252

Abstract:

Gepirone and its pharmaceutically acceptable salts are useful in alleviation of panic disorders which can take the form of clinical syndromes comprising, for example, panic attacks, agoraphobia and phobic anxiety.

US Patent:

48472522, Jul 11, 1989

Filed:

Oct 25, 1988

Appl. No.:

7/262556

Inventors:

Davis L. Temple - Wallingford CT
Michael F. Rafferty - Wheeling IL
Michael S. Eison - Avon CT
Stacy N. Suberg - Farmington CT

Assignee:

Bristol-Myers Company - New York NY

International Classification:

A61K 3150

US Classification:

514252

Abstract:

Tiospirone and its pharmaceutically acceptable salts are useful in alleviation of vascular or vascular-related headaches such as migraine, cluster, muscle-contraction, and combined headaches.